Original Article
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
N Engl J Med 2010; 362:1563-1574April 29, 2010
- Abstract
Background
We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease.
Methods
We randomly assigned 5518 patients with type 2 diabetes who were being treated with open-label simvastatin to receive either masked fenofibrate or placebo. The primary outcome was the first occurrence of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The mean follow-up was 4.7 years.
Results
The annual rate of the primary outcome was 2.2% in the fenofibrate group and 2.4% in the placebo group (hazard ratio in the fenofibrate group, 0.92; 95% confidence interval [CI], 0.79 to 1.08; P=0.32). There were also no significant differences between the two study groups with respect to any secondary outcome. Annual rates of death were 1.5% in the fenofibrate group and 1.6% in the placebo group (hazard ratio, 0.91; 95% CI, 0.75 to 1.10; P=0.33). Prespecified subgroup analyses suggested heterogeneity in treatment effect according to sex, with a benefit for men and possible harm for women (P=0.01 for interaction), and a possible interaction according to lipid subgroup, with a possible benefit for patients with both a high baseline triglyceride level and a low baseline level of high-density lipoprotein cholesterol (P=0.057 for interaction).
Conclusions
The combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone. These results do not support the routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.)
Media in This Article
Figure 1
Lipid Values.Figure 2
Kaplan–Meier Analyses of the Primary Outcome, Expanded Macrovascular Outcome, and Death.Article Activity
- Article
Patients with type 2 diabetes mellitus have an increased incidence of atherosclerotic cardiovascular disease.1-4 This increase is attributable, in part, to associated risk factors, including hypertension and dyslipidemia. The latter is characterized by elevated plasma triglyceride levels, low levels of high-density lipoprotein (HDL) cholesterol, and small, dense low-density lipoprotein (LDL) particles.5,6 The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study was designed to test the effect of intensive treatment of blood glucose and either blood pressure or plasma lipids on cardiovascular outcomes in 10,251 patients with type 2 diabetes who were at high risk for cardiovascular disease. Here we present the findings of the ACCORD lipid trial (ACCORD Lipid).
Although statins are efficacious in patients with type 2 diabetes, rates of cardiovascular events remain elevated in such patients even after statin treatment.7-9 Fibrate therapy in patients with type 2 diabetes reduced the rate of coronary heart disease events in the Veterans Affairs HDL Intervention Trial (VA-HIT; ClinicalTrials.gov number, NCT00035711)10 but not in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial (Current Controlled Trials number, ISRCTN64783481).11 However, a post hoc analysis of data from the FIELD study suggested a benefit for patients with both elevated triglyceride levels and low HDL cholesterol levels.12 Previous fibrate studies in subjects with diabetes10,11 or in those without diabetes13-15 did not address the role of such drugs in patients receiving statin therapy. The hypothesis that we tested in ACCORD Lipid was that in high-risk patients with type 2 diabetes, combination treatment with a fibrate (both to raise HDL cholesterol levels and to lower triglyceride levels) and a statin (to reduce LDL cholesterol levels) would reduce the rate of cardiovascular events, as compared with treatment with a statin alone.
Methods
Study Design
The rationale and designs for the various components of ACCORD have been reported previously.16-20 The ACCORD study was a randomized trial conducted at 77 clinical sites organized into seven networks in the United States and Canada. (For a full list of participating institutions and investigators, see Section 20 in Supplementary Appendix 1, available with the full text of this article at NEJM.org.) The trial was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), and the protocol was approved by a review panel at the NHLBI, as well as by the institutional review board or ethics committee at each center.
In the ACCORD study, all patients were randomly assigned to receive either intensive glycemic control (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a glycated hemoglobin level of 7.0 to 7.9%). The results of this comparison have been reported previously.20 A subgroup of patients in the ACCORD study were also enrolled in the ACCORD Lipid trial and underwent randomization, in a 2-by-2 factorial design, to receive simvastatin plus either fenofibrate or placebo. Randomization occurred between January 11, 2001, and October 29, 2005. End-of-study visits were scheduled between March and June 2009. Additional details regarding the trial protocol and amendments are provided in Supplementary Appendix 2, also available with the full text of this article at NEJM.org.
Eligibility
All patients in the ACCORD study had type 2 diabetes and a glycated hemoglobin level of 7.5% or more. If patients had evidence of clinical cardiovascular disease, the age range was limited to 40 to 79 years; if they had evidence of subclinical cardiovascular disease or at least two additional cardiovascular risk factors, the age range was compressed to 55 to 79 years. Patients were specifically eligible to participate in the lipid trial if they also had the following: an LDL cholesterol level of 60 to 180 mg per deciliter (1.55 to 4.65 mmol per liter), an HDL cholesterol level below 55 mg per deciliter (1.42 mmol per liter) for women and blacks or below 50 mg per deciliter (1.29 mmol per liter) for all other groups, and a triglyceride level below 750 mg per deciliter (8.5 mmol per liter) if they were not receiving lipid therapy or below 400 mg per deciliter (4.5 mmol per liter) if they were receiving lipid therapy. All patients provided written informed consent. Additional details regarding eligibility and the protocol for the enrollment of patients are available in Section 3 in Supplementary Appendix 1.
Study Procedures
Randomization was performed centrally on the trial's Web site with the use of permuted blocks to maintain concealment of study-group assignments. Open-label simvastatin therapy began at the randomization visit, and the masked administration of either fenofibrate or placebo began 1 month later. The initial dose of simvastatin complied with national lipid guidelines at the time the study began.21 The dose of simvastatin was modified over time in response to changing guidelines (see Section 6 in Supplementary Appendix 1).18
At the start of the trial, the dose of fenofibrate was 160 mg per day. Because of a rise in serum creatinine levels in some patients while receiving this dose of fenofibrate,22 starting in 2004, the dose of fenofibrate was adjusted according to the estimated glomerular filtration rate (GFR) with the use of the abbreviated Modification of Diet in Renal Disease (MDRD) equation (see Section 7 in Supplementary Appendix 1).23
A fasting plasma lipid profile was measured at the ACCORD central laboratory at 4, 8, and 12 months after randomization, annually thereafter, and at the end of the study. Safety profiles, including liver-function tests and measurements of creatine kinase levels, were determined at 1, 4, 8, and 12 months after randomization and annually thereafter. If symptoms or signs suggestive of drug-induced toxic effects developed, tests of liver function (including measurement of alanine aminotransferase), creatine kinase, or both were obtained. If liver-function values were elevated, lipid medications were temporarily discontinued; if creatine kinase values were elevated, lipid medications were permanently discontinued.
Prespecified Outcomes
The prespecified primary outcome was the first occurrence of a major cardiovascular event, including nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. Secondary outcomes included the combination of the primary outcome plus revascularization or hospitalization for congestive heart failure (termed the “expanded macrovascular outcome”); a combination of a fatal coronary event, nonfatal myocardial infarction, or unstable angina (termed “major coronary disease events”); nonfatal myocardial infarction; fatal or nonfatal stroke; nonfatal stroke; death from any cause; death from cardiovascular causes; and hospitalization or death due to heart failure. Definitions of each prespecified outcome and methods of ascertainment are detailed in Section 8 in Supplementary Appendix 1.
Study Oversight
Fenofibrate and matching placebo were donated by Abbott Laboratories; simvastatin was donated by Merck. The drug manufacturers had no role in the design of the study, in the accrual or analysis of the data, or in the preparation of the manuscript. All authors vouch for the accuracy and completeness of the reported data.
Statistical Analysis
The study was designed to recruit 5800 patients, with a power of 87% to detect a 20% reduction in the rate of the primary outcome for patients in the fenofibrate group, as compared with placebo, assuming a two-sided alpha level of 0.05, a primary outcome rate of 2.4% per year in the placebo group, and an average follow-up of approximately 5.6 years for patients who did not have an event. All statistical analyses were conducted at the coordinating center with the use of S-Plus software, version 8.0 (Insightful) or SAS software, version 9.1 (SAS Institute). Baseline characteristics were compared between study groups with the use of the chi-square test, Fisher's exact test, Wilcoxon rank-sum test, and two-sample t-tests. The incidence of key safety outcomes was compared with the use of Fisher's exact test.
Analyses of primary and secondary outcomes were performed with the use of time-to-event methods, according to the intention-to-treat principle, and occurrences of outcomes were compared with the use of hazard ratios and 95% confidence intervals. Two-sided P values were obtained from likelihood ratio tests from Cox proportional-hazards regression analyses. The Cox models contained a term representing study-group assignment plus terms for the following prespecified variables: assignment to the intensive glycemic intervention, the seven clinical-center networks, and the presence or absence of a previous cardiovascular event. Between-group differences were also examined in prespecified subgroups on 10 baseline characteristics (see Section 9 in Supplementary Appendix 1). Event rates are expressed as the percentage of events per years of follow-up, taking into account the censoring of follow-up data. Kaplan–Meier estimates were used to obtain the proportion of patients who had an event during follow-up.
The primary outcome and total rates of death were monitored by the data and safety monitoring board, using O'Brien–Fleming boundaries determined by the Lan–DeMets approach. For the primary outcome and rates of death, P values have been adjusted to account for the number, timing, and results of interim analyses. Further details regarding the analytic methods are available in Section 11 in Supplementary Appendix 1.
Results
Study Patients
A total of 5518 patients were enrolled in the ACCORD Lipid study, with 2765 assigned to receive fenofibrate plus simvastatin and 2753 assigned to receive placebo plus simvastatin. Baseline characteristics were similar between the two groups (Table 1Table 1
Baseline Characteristics of the Patients.). The mean age was 62 years, and 31% of the patients were female. Thirty-seven percent had a history of a cardiovascular event, and about 60% were taking a statin before enrollment.The mean duration of follow-up was 4.7 years for the primary outcome and 5.0 years for total rates of death. At the final study visit, 77.3% of the patients in the fenofibrate group and 81.3% of those in the placebo group were taking their assigned medication. At the end of the study, approximately 80% of patients were still taking simvastatin in each group, and an additional 6% were taking an alternative study-approved agent for lowering LDL cholesterol. Additional details related to adherence are in presented in Section 12 in Supplementary Appendix 1. The average daily dose of simvastatin during the follow-up period was 22.3 mg in the fenofibrate group and 22.4 mg in the placebo group.
Safety
Elevations of creatine kinase of more than 10 times the upper limit of the normal range at any time during the trial occurred in 10 patients (0.4%) in the fenofibrate group and 9 (0.3%) in the placebo group (for details, see Section 13 in Supplementary Appendix 1). An elevation in alanine aminotransferase of more than three times the upper limit of the normal range occurred in 52 patients (1.9%) in the fenofibrate group and 40 (1.5%) in the placebo group.
As noted in other fenofibrate trials,11,22, mean serum creatinine levels increased from 0.93 to 1.10 mg per deciliter (82 to 97 μmol per liter) in the fenofibrate group within the first year and remained relatively stable thereafter. In the placebo group, mean serum creatinine levels increased from 0.93 to 1.04 mg per deciliter (82 to 92 μmol per liter) during the course of the trial (see Section 15 in Supplementary Appendix 1). The study drug was discontinued by 66 patients (2.4%) in the fenofibrate group and 30 (1.1%) in the placebo group because of a decrease in the estimated GFR. At the last clinic visit, 440 patients (15.9%) in the fenofibrate group and 194 (7.0%) in the placebo group were receiving a reduced dose of either fibrate or placebo because of a decreased estimated GFR. There was no significant between-group difference in the incidence of both hemodialysis and end-stage renal disease (75 patients in the fenofibrate group vs. 77 in the placebo group). There was a lower incidence of both microalbuminuria and macroalbuminuria in the fenofibrate group than in the placebo group (see Section 13 in Supplementary Appendix 1).
Plasma Lipids
By the end of the study, the mean LDL cholesterol level fell from 100.0 to 81.1 mg per deciliter (2.59 to 2.10 mmol per liter) in the fenofibrate group and from 101.1 to 80.0 mg per deciliter (2.61 to 2.07 mmol per liter) in the placebo group (Figure 1Figure 1
Lipid Values., and Section 16 in Supplementary Appendix 1). Mean HDL cholesterol levels increased from 38.0 to 41.2 mg per deciliter (0.98 to 1.07 mmol per liter) in the fenofibrate group and from 38.2 to 40.5 mg per deciliter (0.99 to 1.05 mmol per liter) in the placebo group. Median plasma triglyceride levels decreased from 164 to 122 mg per deciliter (1.85 to 1.38 mmol per liter) in the fenofibrate group and from 160 to 144 mg per deciliter (1.81 to 1.63 mmol per liter) in the placebo group.Clinical Outcomes
The annual rate of the primary outcome was 2.2% in the fenofibrate group, as compared with 2.4% in the placebo group (hazard ratio in the fenofibrate group, 0.92; 95% confidence interval [CI], 0.79 to 1.08; P=0.32 after adjustment for monitoring) (Table 2Table 2
Prespecified Primary and Secondary Outcomes. and Figure 2Figure 2Kaplan–Meier Analyses of the Primary Outcome, Expanded Macrovascular Outcome, and Death.). Hazard ratios for the secondary outcomes, including the individual components of the primary outcome, ranged from 0.82 to 1.17 (P≥0.10 for all comparisons) (Table 2). Annual rates of death from all causes were 1.5% in the fenofibrate group and 1.6% in the placebo group (hazard ratio, 0.91; 95% CI, 0.75 to 1.10; P=0.33 for the adjusted comparison). Specific causes of death and enlarged versions of the Figure 2 insets are presented in Sections 17 and 18 in Supplementary Appendix 1.Study-group effects on the primary outcome across prespecified baseline subgroups are shown in Figure 3Figure 3
Hazard Ratios for the Primary Outcome in Prespecified Subgroups.. Only sex showed evidence of an interaction according to study group: the primary outcome for men was 11.2% in the fenofibrate group versus 13.3% in the placebo group, whereas the rate for women was 9.1% in the fenofibrate group versus 6.6% in the placebo group (P=0.01 for interaction). There was also a nonsignificant suggestion of heterogeneity when patients who had a triglyceride level in the highest third (≥204 mg per deciliter [≥2.30 mmol per liter]) and an HDL cholesterol level in the lowest third (≤34 mg per deciliter [≤0.88 mmol per liter]) were compared with all the other patients (P=0.057 for interaction). In this subgroup of patients with high triglyceride levels and low HDL cholesterol levels, the primary outcome rate was 12.4% in the fenofibrate group, versus 17.3% in the placebo group, whereas such rates were 10.1% in both study groups for all other patients. Discussion
In this trial, we tested the hypothesis that the use of fenofibrate to increase plasma HDL cholesterol levels and to reduce plasma triglyceride levels in patients with type 2 diabetes who were already receiving simvastatin therapy would result in an additional cardiovascular benefit, as compared with simvastatin therapy alone. However, the rates of the primary outcome did not differ significantly between the fenofibrate group and the placebo group during 4.7 years of treatment and follow-up.
When a study does not support the central hypothesis, it is critical to examine potential reasons for this outcome. One possibility is that the addition of fenofibrate to statin therapy benefited only certain subgroups of patients and that other subgroups that did not benefit diluted the overall effect. Our study was part of a factorial design to simultaneously test the effects of intensive glycemic control17,20 and combination lipid therapy on cardiovascular outcomes. To allow for efficient enrollment of the entire cohort of 10,000 patients while including a group for whom the results of the lipid trial could be widely extrapolated, we used broader inclusion criteria for plasma lipid levels than might have been used if the lipid trial had been an independent study.
A second possibility is that the trial might have had fewer events than anticipated. However, the annual rate of 2.4% in the placebo group was the rate used in the power calculations. Another possibility is poor adherence to the experimental protocol. However, adherence at the end of the study was approximately 80% in both the fenofibrate and placebo groups and 80% for simvastatin. Furthermore, unlike the FIELD study, in which there was a disproportionate drop-in to statin therapy in the placebo group,11 the prevalence of statin therapy in our study was similar in the fenofibrate and placebo groups. A fourth possibility is that fenofibrate is not as effective as gemfibrozil, which showed benefit in the Helsinki Heart Study (HHS) and VA-HIT,13,15 studies in which there was no background statin therapy.
In examined subgroups, only sex had a significant interaction with treatment: men seemed to benefit from fenofibrate therapy, whereas there was a trend toward harm among women. This is in contrast to the results of the FIELD study, in which there was no significant interaction effect between treatment and sex on outcome.11
There was also a suggestion of heterogeneity according to baseline lipid levels: patients who had both a triglyceride level in the highest third and an HDL cholesterol level in the lowest third (which we termed the subgroup with dyslipidemia) appeared to benefit from fenofibrate, whereas all other patients receiving fenofibrate did not. The mean baseline HDL cholesterol level in the subgroup with dyslipidemia was 29.5 mg per deciliter (0.76 mmol per liter), and the median triglyceride level was 284 mg per deciliter (3.21 mmol per liter), in contrast to the rest of the patients, in whom the mean HDL cholesterol level was 39.9 mg per deciliter (1.03 mmol per liter) and the median triglyceride level was 144 mg per deciliter (1.63 mmol per liter). From baseline to 4 months in the fenofibrate group, the HDL cholesterol level rose 12.9% and the triglyceride level fell 35.0% among patients in the subgroup with dyslipidemia, as compared with a 7.3% rise in the HDL cholesterol level and a 24.1% decrease in the triglyceride level among all other patients receiving fenofibrate. The treatment interaction according to sex for the entire ACCORD Lipid cohort was not observed in the subgroup with dyslipidemia (data not shown).
The results for patients in the subgroup with dyslipidemia are similar to those in post hoc subgroup analyses performed in three of four major fibrate trials, including HHS,24 the Bezafibrate Infarction Prevention (BIP) trial,14 and the FIELD trial12 (see Section 19 in Supplementary Appendix 1 for details). Our subgroup results and those of these previous trials support the view that the addition of fenofibrate to a statin may benefit patients with type 2 diabetes who have substantial dyslipidemia. The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25
Previous studies11,22 have raised concern about increases in serum creatinine levels during fenofibrate treatment. Serum creatinine levels increased in the fenofibrate group soon after randomization but thereafter remained constant, as compared with those in the placebo group. In the FIELD study, there was a return of serum creatinine to baseline levels by 8 weeks after the end of the trial.11 In our study, there was no significant difference in the incidence of end-stage renal disease or need for dialysis between the fenofibrate group and the placebo group. There was a reduction in both microalbuminuria and macroalbuminuria in the fenofibrate group. There has also been long-standing concern regarding an increased risk of myositis or rhabdomyolysis when fibrates are added to statins.26,27 No evidence for such a risk was noted in our study, a finding that was compatible with evidence that fenofibrate, in contrast to gemfibrozil, does not increase plasma concentrations of statins.28
In conclusion, we found that combination therapy with the use of fenofibrate and simvastatin (at a daily dose of 40 mg or less) did not reduce rates of cardiovascular disease, as compared with simvastatin alone. Our findings do not support the use of combination fibrate–statin therapy, rather than statin therapy alone, to reduce cardiovascular risk in the majority of patients with type 2 diabetes who are at high risk for cardiovascular disease.
Supported by the National Heart, Lung, and Blood Institute (contracts N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAAY1-HC-9035, and IAAY1-HC-1010), the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, the National Eye Institute, the Centers for Disease Control and Prevention, and General Clinical Research Centers at many sites. The following companies provided study medications, equipment, or supplies: Abbott Laboratories, Amylin Pharmaceutical, AstraZeneca Pharmaceuticals, Bayer HealthCare, Closer Healthcare, GlaxoSmithKline Pharmaceuticals, King Pharmaceuticals, Merck, Novartis Pharmaceuticals, Novo Nordisk, Omron Healthcare, Sanofi-Aventis, and Takeda Pharmaceuticals.
Dr. Ginsberg reports receiving consulting fees from Merck, Merck Schering-Plough, Bristol-Myers Squibb, AstraZeneca, Abbott, Roche, Isis/Genzyme, GlaxoSmithKline, Novartis, Pfizer, and Regeneron/Sanofi-Aventis and grant support from Merck, Isis/Genzyme, Roche, and AstraZeneca; Dr. Elam, receiving consulting fees from Pfizer, Abbott, and Merck Schering-Plough; Dr. Crouse, receiving consulting fees from the National Lipid Association, AstraZeneca, Merck, and Merck Schering-Plough and grant support from AstraZeneca; Dr. Leiter, receiving consulting fees from AstraZeneca, Merck, Pfizer, Roche, and Solvay and grant support from AstraZeneca, Merck, Pfizer, and Roche; Dr. Linz, having an equity interest in Pfizer, Novartis, and AstraZeneca; Dr. Buse, receiving consulting fees from Novo Nordisk, Amylin, Becton Dickinson, Eli Lilly, Hoffmann–La Roche, GlycoMark, Wyeth, Daiichi Sankyo, Bristol-Myers Squibb, Bayhill Therapeutics, LipoScience, MannKind, Veritas, MicroIslet, GlaxoSmithKline, Abbott, Exsulin, and GI Dynamics and grant support from Amylin, Novo Nordisk, Medtronic, Eli Lilly, Novartis, Tolerex, Osiris, Halozyme, Pfizer, Hoffmann–La Roche, InterKrin, Merck, Sanofi-Aventis, Dexcom, Johnson & Johnson, Bristol-Myers Squibb, and Fujisawa, having an equity interest in Insulet, and providing expert testimony for Novo Nordisk; Dr. Gerstein, receiving consulting fees from Sanofi-Aventis, GlaxoSmithKline, Eli Lilly, Novo Nordisk, AstraZeneca, Bristol-Myers Squibb, Roche, Medtronic, Merck, Bayer, Bioavail, and Janssen-Ortho, grant support from Sanofi-Aventis, GlaxoSmithKline, Novo Nordisk, Merck, Pronova, and Roche, and lecture fees from Sanofi-Aventis, GlaxoSmithKline, Solvay, Boehringer Ingelheim, Servier, Bayer, Eli Lilly, Novo Nordisk, and Takeda; Dr. Probstfield, receiving grant support from Sanofi-Aventis, Boehringer Ingelheim, and Abbott; Dr. Grimm, receiving consulting and lecture fees and grant support from Pfizer, Merck, and Novartis, consulting and lecture fees from Takeda, and lecture fees from AstraZeneca, Forest Laboratories, and Schering-Plough; Dr. Bigger, receiving consulting fees from Merck and Roche; Dr. Goff, receiving consulting fees from Takeda and grant support from Merck; and Dr. Cushman, receiving consulting fees from Novartis, Takeda, Sanofi-Aventis, Bristol-Myers Squibb, King, Daiichi-Sankyo, Gilead, Theravance, Pharmacopeia, and Sciele and grant support from Novartis, GlaxoSmithKline, and Merck.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
No other potential conflict of interest relevant to this article was reported.
The members of the Writing Committee (Henry N. Ginsberg, M.D., Marshall B. Elam, M.D., Laura C. Lovato, M.S., John R. Crouse III, M.D., Lawrence A. Leiter, M.D., Peter Linz, M.D., William T. Friedewald, M.D., John B. Buse, M.D., Ph.D., Hertzel C. Gerstein, M.D., Jeffrey Probstfield, M.D., Richard H. Grimm, M.D., Ph.D., Faramarz Ismail-Beigi, M.D., Ph.D., J. Thomas Bigger, M.D., David C. Goff, Jr., M.D., Ph.D., William C. Cushman, M.D., Denise G. Simons-Morton, M.D., Ph.D., and Robert P. Byington, Ph.D.) assume responsibility for the integrity of the article.
This article (10.1056/NEJMoa1001282) was published on March 14, 2010, and updated on March 18, 2010, at NEJM.org.
Source Information
Address reprint requests to Dr. Ginsberg at the Department of Medicine, Columbia University College of Physicians and Surgeons, Rm. PH 10-305, New York, NY 10032, or at hng1@columbia.edu.
The members of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group are listed in Section 20 in Supplementary Appendix 1, available with the full text of this article at NEJM.org. The affiliations of members of the Writing Committee are listed in the Appendix.
Appendix
The affiliations of the members of the writing committee are as follows: the Department of Medicine, Columbia University College of Physicians and Surgeons, New York (H.N.G.); Memphis Veterans Affairs Medical Center, Memphis (M.B.E., W.C.C.); the Department of Public Health Sciences (L.C.L., D.C.G., R.P.B.) and Preventive Cardiology Program (J.R.C.), Wake Forest University School of Medicine, Winston-Salem, NC; University of Toronto, Toronto (L.A.L.); Naval Medical Center, San Diego, CA (P.L.); the Departments of Biostatistics and Epidemiology, Columbia University Mailman School of Public Health, New York (W.T.F.); the Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill (J.B.B.); the Department of Medicine and the Population Health Research Institute, McMaster University, Hamilton, ON, Canada (H.C.G.); the University of Washington, Seattle (J.P.); the Berman Center for Outcomes and Clinical Research, Minneapolis (R.H.G.), the Departments of Medicine and Physiology and Biophysics, Case Western Reserve University, Cleveland (F.I.-B.); the Division of Cardiology, Columbia University College of Physicians and Surgeons, New York (J.T.B.); and the National Heart, Lung, and Blood Institute, Bethesda, MD (D.G.S.-M.).
- References
References
1
Almdal T ,Scharling H ,Jensen JS ,Vestergaard H . The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422-1426
CrossRef | Web of Science | Medline2
Stamler J ,Vaccaro O ,Neaton JD ,Wentworth D . Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444
CrossRef | Web of Science | Medline3
Haffner SM ,Lehto S ,Ronnemaa T ,Pyorala K ,Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234
Full Text | Web of Science | Medline4
Miettinen H ,Lehto S ,Salomaa V , et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998;21:69-75
CrossRef | Web of Science | Medline5
Chahil TJ ,Ginsberg HN . Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006;35:491-510
CrossRef | Web of Science | Medline6
Turner RC ,Millns H ,Neil HA , et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828
CrossRef | Web of Science | Medline7
Collins R ,Armitage J ,Parish S ,Sleigh P ,Peto R . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016
CrossRef | Web of Science | Medline8
Shepherd J ,Barter P ,Carmena R , et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-1226
CrossRef | Web of Science | Medline9
Colhoun HM ,Betteridge DJ ,Durrington PN , et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
CrossRef | Web of Science | Medline10
Rubins HB ,Robins SJ ,Collins D , et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-2604
CrossRef | Web of Science | Medline11
Keech A ,Simes RJ ,Barter P , et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861[Erratum, Lancet 2006;368:1415, 1420.]
CrossRef | Web of Science | Medline12
Scott R ,O'Brien R ,Fulcher G , et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-498
CrossRef | Web of Science | Medline13
Frick MH ,Elo O ,Haapa K , et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245
Full Text | Web of Science | Medline14
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27
Web of Science | Medline15
Rubins HB ,Robins SJ ,Collins D , et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418
Full Text | Web of Science | Medline16
Buse JB ,Bigger JT ,Byington RP , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i
CrossRef | Web of Science | Medline17
Goff DC Jr ,Gerstein HC ,Ginsberg HN , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:4i-20i
Web of Science | Medline18
Ginsberg HN ,Bonds DE ,Lovato LC , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:56i-67i
CrossRef | Web of Science | Medline19
Cushman WC ,Grimm RH Jr ,Cutler JA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:44i-55i
CrossRef | Web of Science | Medline20
The Action to Control Cardiovascular Risk in Diabetes Study Group
Full Text | Web of Science | Medline21
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
CrossRef | Web of Science22
Genest J ,Frohlich J ,Steiner G . Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 2004;93:848-853
CrossRef | Web of Science | Medline23
Levey AS ,Bosch JP ,Lewis JB ,Greene T ,Rogers N ,Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
Web of Science | Medline24
Manninen V ,Tenkanen L ,Koskinen P , et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45
Web of Science | Medline25
Grundy SM ,Cleeman JI ,Merz CN , et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239[Erratum, Circulation 2004;110:763.]
CrossRef | Web of Science | Medline26
Pasternak RC ,Smith SC Jr ,Bairey-Merz CN ,Grundy SM ,Cleeman JI ,Lenfant C . ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-1028
CrossRef | Web of Science | Medline27
Jones PH ,Davidson MH . Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-122
CrossRef | Web of Science | Medline28
Bergman AJ ,Murphy G ,Burke J , et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44:1054-1062
CrossRef | Web of Science | Medline
- Citing Articles (198)
Citing Articles
1
Gregory G. Schwartz. (2012) New Horizons for Cholesterol Ester Transfer Protein Inhibitors. Current Atherosclerosis Reports 14:1, 41-48
CrossRef2
Uchechukwu K. Sampson, Sergio Fazio, MacRae F. Linton. (2012) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports 14:1, 1-10
CrossRef3
Gianpaolo Reboldi, Giorgio Gentile, Valeria Maria Manfreda, Fabio Angeli, Paolo Verdecchia. (2012) Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes. Current Cardiology Reports 14:1, 89-96
CrossRef4
Kwang Kon Koh, Michael J. Quon, Kwen-Chul Shin, Soo Lim, Yonghee Lee, Ichiro Sakuma, Kyounghoon Lee, Seung Hwan Han, Eak Kyun Shin. (2012) Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 220:2, 537-544
CrossRef5
Denise E. Bonds. (2012) Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes. Current Cardiovascular Risk Reports 6:1, 102-107
CrossRef6
Sayuri N. Friedland, Aaron Leong, Kristian B. Filion, Jacques Genest, Iliana C. Lega, Salvatore Mottillo, Paul Poirier, Jennifer Reoch, Mark J. Eisenberg. (2012) The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists. The American Journal of Medicine 125:2, 126-133
CrossRef7
Boon How Chew, Mastura Ismail, Ping Yein Lee, Sri Wahyu Taher, Jamaiyah Haniff, Feisul Idzwan Mustapha, Mohd Adam Bujang. (2012) Determinants of uncontrolled dyslipidaemia among adult type 2 diabetes in Malaysia: The Malaysian Diabetes Registry 2009. Diabetes Research and Clinical Practice
CrossRef8
Sud Ramachandran, Ahmed Abbas, Sanjay Saraf, Jessie Raju, Christina Jewkes, Alan F Jones. (2012) Significant Increase in High-Density Lipoprotein Cholesterol with Fibrates Is Associated with Low Pretreatment High-Density Lipoprotein Cholesterol: Findings from An Outpatient Clinic Setting. Metabolic Syndrome and Related Disorders120127065325006
CrossRef9
Brian G. Drew, Kerry-Anne Rye, Stephen J. Duffy, Philip Barter, Bronwyn A. Kingwell. (2012) The emerging role of HDL in glucose metabolism. Nature Reviews Endocrinology
CrossRef10
A. F. H. Stalenhoef, M. H. Davidson, J. G. Robinson, T. Burgess, R. Duttlinger-Maddux, D. Kallend, A. C. Goldberg, H. Bays. (2012) Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes, Obesity and Metabolism 14:1, 30-39
CrossRef11
I. Kouroumichakis, N. Papanas, P. Zarogoulidis, V. Liakopoulos, E. Maltezos, D.P. Mikhailidis. (2012) Fibrates: Therapeutic potential for diabetic nephropathy?. European Journal of Internal Medicine
CrossRef12
Jing Liu, Wei Wang, Miao Wang, Jiayi Sun, Jun Liu, Yan Li, Yue Qi, Zhaosu Wu, Dong Zhao. (2012) Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: A 15-year follow-up of the Chinese Multi-provincial Cohort Study. Diabetes Research and Clinical Practice
CrossRef13
D E Gutstein, R Krishna, D Johns, H K Surks, H M Dansky, S Shah, Y B Mitchel, J Arena, J A Wagner. (2012) Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction. Clinical Pharmacology & Therapeutics 91:1, 109-122
CrossRef14
Yehuda Handelsman, Vivian Fonseca, Julio Rosenstock. (2012) Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?. Expert Review of Clinical Pharmacology 5:1, 43-54
CrossRef15
Nikhil Tandon, Mohammed K. Ali, K.M. Venkat Narayan. (2012) Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. American Journal Cardiovascular Drugs1
CrossRef16
Anton P. van de Woestijne, Annemarie M.J. Wassink, Houshang Monajemi, An-Ho Liem, Hendrik M. Nathoe, Yolanda van der Graaf, Frank L.J. Visseren. (2012) Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol. International Journal of Cardiology
CrossRef17
Sang-Hak Lee, Kyoung-Im Cho, Jang-Young Kim, Young Keun Ahn, Seung-Woon Rha, Yong-Jin Kim, Yun-Seok Choi, Si Wan Choi, Dong Woon Jeon, Pil-Ki Min, Dong-Ju Choi, Sang Hong Baek, Kwon Sam Kim, Young Sup Byun, Yangsoo Jang. (2012) Non-Lipid Effects of Rosuvastatin-Fenofibrate Combination Therapy in High-Risk Asian Patients with Mixed Hyperlipidemia. Atherosclerosis
CrossRef18
Itoro E. Elijah, Elisabet Børsheim, Dirk M. Maybauer, Celeste C. Finnerty, David N. Herndon, Marc O. Maybauer. (2012) Role of the PPAR-α agonist fenofibrate in severe pediatric burn. Burns
CrossRef19
2011. Combination Therapies. , 524-532.
CrossRef20
2011. Complications Associated with Diabetes. , 201-249.
CrossRef21
Benoit J. Arsenault, Emilie Pelletier Beaumont, Jean-Pierre Després, Eric Larose. (2011) Mapping body fat distribution: A key step towards the identification of the vulnerable patient?. Annals of Medicine1-15
CrossRef22
Zachary Bloomgarden, Yehuda Handelsman, Daniel Einhorn. (2011) Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. Journal of Diabetes 3:4, 257-260
CrossRef23
Susan R. Kirsh, David C. Aron. (2011) Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. Drugs & Aging 28:12, 945-960
CrossRef24
Stephanie Neuhold, Michael Resl, Martin Huelsmann, Guido Strunk, Christopher Adlbrecht, Claus Rath, Rudolf Prager, Anton Luger, Martin Clodi, Richard Pacher. (2011) Repeat measurements of glycated haemoglobin A1c and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus. European Journal of Clinical Investigation 41:12, 1292-1298
CrossRef25
Shu-Chang An, Li-Li Xu, Feng-Di Li, Lin-Lin Bao, Chuan Qin, Zhan-Cheng Gao. (2011) Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic. Medical Hypotheses 77:6, 1054-1057
CrossRef26
Benoit J Arsenault, Jean-Pierre Després, S Matthijs Boekholdt. (2011) Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?. Clinical Lipidology 6:6, 639-651
CrossRef27
Beatriz G. Talayero, Frank M. Sacks. (2011) The Role of Triglycerides in Atherosclerosis. Current Cardiology Reports 13:6, 544-552
CrossRef28
Ariel Brautbar, Daniel Covarrubias, John Belmont, Fremiet Lara-Garduno, Salim S. Virani, Peter H. Jones, Suzanne M. Leal, Christie M. Ballantyne. (2011) Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 219:2, 737-742
CrossRef29
Barry S. Peters, Anthony S. Wierzbicki, Graeme Moyle, Davaki Nair, Norbert Brockmeyer. (2011) The Effect of a 12-Week Course of Omega-3 Polyunsaturated Fatty Acids on Lipid Parameters in Hypertriglyceridemic Adult HIV-infected Patients Undergoing HAART: A Randomized, Placebo-Controlled Pilot Trial. Clinical Therapeutics
CrossRef30
Peter P. Toth, Christie M. Ballantyne, Michael H. Davidson, Joanne E. Tomassini, Dena Rosen Ramey, David Neff, Andrew M. Tershakovec, X. Henry Hu, Kaan Tunceli. (2011) Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. Journal of Clinical Lipidology
CrossRef31
L. A. Leiter, P. Lundman, P. M. da Silva, H. Drexel, C. Jünger, A. K. Gitt, . (2011) Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabetic Medicine 28:11, 1343-1351
CrossRef32
Michel Farnier, Jean Ducobu, Leszek Bryniarski. (2011) Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. Current Medical Research and Opinion 27:11, 2165-2173
CrossRef33
Anthony S. Wierzbicki. (2011) HDL: who needs it?. International Journal of Clinical Practice 65:11, 1111-1113
CrossRef34
Morali D. Sharma, John Alan Farmer, Alan Garber. (2011) Type 2 diabetes and cardiovascular risk factors. Current Medical Research and Opinion 27:S3, 1-5
CrossRef35
Robert Krysiak, Anna Gdula-Dymek, Boguslaw Okopien. (2011) The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia. European Journal of Clinical Pharmacology 67:11, 1109-1117
CrossRef36
Marianna Maranghi, Anne Hiukka, Robert Badeau, Jouko Sundvall, Matti Jauhiainen, Marja-Riitta Taskinen. (2011) Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: A FIELD substudy. Atherosclerosis 219:1, 259-265
CrossRef37
Kate McKeage, Gillian M. Keating. (2011) Fenofibrate. Drugs 71:14, 1917-1946
CrossRef38
Gregory A. Nichols, Suma Vupputuri, A. Gabriela Rosales. (2011) Change in High-Density Lipoprotein Cholesterol and Risk of Subsequent Hospitalization for Coronary Artery Disease or Stroke Among Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology 108:8, 1124-1128
CrossRef39
Eric A. Schwartz, Peter D. Reaven. (2011) Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
CrossRef40
Alberto Zambon. (2011) Residual cardiovascular risk in secondary prevention. Internal and Emergency Medicine 6:S1, 61-68
CrossRef41
A. P. van de Woestijne, H. Monajemi, E. Kalkhoven, F. L. J. Visseren. (2011) Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obesity Reviews 12:10, 829-840
CrossRef42
Savitha Subramanian, Alan Chait. (2011) Hypertriglyceridemia secondary to obesity and diabetes. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
CrossRef43
Nivee P. Amin, Michael J. Blaha, Grant V. Chow, Roger S. Blumenthal, Dominique Ashen. (2011) Comprehensive Lipid Management in the Coronary Artery Disease Patient. Current Cardiovascular Risk Reports 5:5, 399-406
CrossRef44
Juliana C.N. Chan, Siew Pheng Chan, Chaicharn Deerochanawong, Ruby T. Go, Kok-Onn Lee, Ronald Ching-Wan Ma, Chang-Yu Pan, Wayne H-H. Sheu, Philip Barter. (2011) Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don’t know. Diabetes Research and Clinical Practice 94:1, 1-13
CrossRef45
A.C.I. Boullart, J. de Graaf, A.F. Stalenhoef. (2011) Serum triglycerides and risk of cardiovascular disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
CrossRef46
B. Vergès. (2011) Quelle place pour les fibrates après l’étude ACCORD-Lipids ?. Médecine des Maladies Métaboliques 5:5, 537-539
CrossRef47
Diego Vanuzzo. (2011) The epidemiological concept of residual risk. Internal and Emergency Medicine 6:S1, 45-51
CrossRef48
Claudio Cimminiello. (2011) What intervention trials don’t tell us: the residual risk in primary prevention. Internal and Emergency Medicine 6:S1, 53-60
CrossRef49
Xanthia F. Samaropoulos, Laney Light, Walter T. Ambrosius, Santica M. Marcovina, Jeffrey Probstfield, David C. Goff Jr. (2011) The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research and Clinical Practice
CrossRef50
M. K. Rutter, R. W. Nesto. (2011) Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. European Heart Journal 32:18, 2247-2255
CrossRef51
Anna Marino, Aysha Inankur, Lisa Tannock. (2011) New-onset diabetes after transplantation: focus on treatment strategies. Diabetes Management 1:5, 529-544
CrossRef52
G.B. John Mancini, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A. Hegele, Dominic Ng, Janet Pope. (2011) Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology 27:5, 635-662
CrossRef53
Michael S. Lauer, Richard Hodes. (2011) Commentary: Epidemiology, Comparative Effectiveness Research, and the National Institutes of Health. Epidemiology 22:5, 625-628
CrossRef54
R.S. Rosenson, P. Fioretto, P.M. Dodson. (2011) Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis 218:1, 13-18
CrossRef55
Mukul Sharma. (2011) Combination therapy for dyslipidemia. Current Opinion in Cardiology 26:5, 420-423
CrossRef56
M. John Chapman, Jan S. Redfern, Mark E. McGovern, Philippe Giral. (2011) Optimal pharmacotherapy to combat the atherogenic lipid triad. Current Opinion in Cardiology 26:5, 403-411
CrossRef57
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2011) Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. Clínica e Investigación en Arteriosclerosis 23:5, 230-239
CrossRef58
Rebecca L. Attridge, William D. Linn, Laurajo Ryan, Jim Koeller, Christopher R. Frei. (2011) Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. Journal of Clinical Lipidology
CrossRef59
Goldfine, Allison B., Kaul, Sanjay, Hiatt, William R., . (2011) Fibrates in the Treatment of Dyslipidemias — Time for a Reassessment. New England Journal of Medicine 365:6, 481-484
Full Text60
Michael H. Davidson. (2011) Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nature Reviews Cardiology 8:10, 543-544
CrossRef61
Meng Lee, Jeffrey L. Saver, Amytis Towfighi, Jessica Chow, Bruce Ovbiagele. (2011) Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis 217:2, 492-498
CrossRef62
Jerzy-Roch Nofer. (2011) Hyperlipidemia and cardiovascular disease. Current Opinion in Lipidology 22:4, 319-321
CrossRef63
Gillian M. Keating. (2011) Fenofibrate. American Journal Cardiovascular Drugs 11:4, 227-247
CrossRef64
Sandeep A. Saha, Rohit R. Arora. (2011) Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology 22:4, 270-276
CrossRef65
Klaus G Parhofer. (2011) Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clinical Lipidology 6:4, 401-411
CrossRef66
Sherita Hill Golden. (2011) Emerging Therapeutic Approaches for the Management of Diabetes Mellitus and Macrovascular Complications. The American Journal of Cardiology 108:3, 59B-67B
CrossRef67
Nadia Khoury, Anne Carol Goldberg. (2011) The Use of Fibric Acid Derivatives in Cardiovascular Prevention. Current Treatment Options in Cardiovascular Medicine 13:4, 335-342
CrossRef68
Altan Onat. (2011) Metabolic syndrome: nature, therapeutic solutions and options. Expert Opinion on Pharmacotherapy 12:12, 1887-1900
CrossRef69
Terry A. Jacobson. (2011) Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Mayo Clinic Proceedings 86:8, 762-780
CrossRef70
Javier Sanz, Valentin Fuster. (2011) The Year in Atherothrombosis. Journal of the American College of Cardiology 58:8, 779-791
CrossRef71
Serena Tonstad, Jean-Pierre Després. (2011) Treatment of lipid disorders in obesity. Expert Review of Cardiovascular Therapy 9:8, 1069-1080
CrossRef72
Yehuda Handelsman, Paul S. Jellinger. (2011) Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 13:8, 613-620
CrossRef73
Gerald F Watts, Fredrik Karpe. (2011) Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?. Expert Review of Cardiovascular Therapy 9:8, 987-997
CrossRef74
Deepthi Vodnala, Sanjay Rajagopalan, Robert D. Brook. (2011) Medical Management of the Patient with Intermittent Claudication. Cardiology Clinics 29:3, 363-379
CrossRef75
Merlin C Thomas, Per-Henrik Groop. (2011) New approaches to the treatment of nephropathy in diabetes. Expert Opinion on Investigational Drugs 20:8, 1057-1071
CrossRef76
Ralph A. DeFronzo, Muhammad Abdul-Ghani. (2011) Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. The American Journal of Cardiology 108:3, 3B-24B
CrossRef77
Theodosios D Filippatos, Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, 1945-1958
CrossRef78
, , Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, , J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 32:14, 1769-1818
CrossRef79
Ana María Wägner, Jose Luis Sánchez-Quesada, Sonia Benítez, Cristina Bancells, Jordi Ordóñez-Llanos, Antonio Pérez. (2011) Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Research and Clinical Practice 93:1, e25-e28
CrossRef80
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217:1, 3-46
CrossRef81
William J Elliott. (2011) What should be the blood pressure target for diabetic patients?. Current Opinion in Cardiology 26:4, 308-313
CrossRef82
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217, 1-44
CrossRef83
Jean-Louis Chiasson, Sophie Bernard. (2011) Reducing cardiovascular risk factors in patients with prediabetes. Diabetes Management 1:4, 423-438
CrossRef84
Alice YY Cheng, Lawrence A Leiter. (2011) ACCORD microvascular and Eye substudy: should the results change our practice?. Diabetes Management 1:4, 389-396
CrossRef85
A D Wright, P M Dodson. (2011) Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye 25:7, 843-849
CrossRef86
SJ Hamilton, GT Chew, TME Davis, BGA Stuckey, GF Watts. (2011) Hypertriglyceridaemia in statin-treated type 2 diabetic patients. Practical Diabetes International 28:6, 257-260
CrossRef87
J. B. Echouffo-Tcheugui, M. K. Ali, S. J. Griffin, K. M. V. Narayan. (2011) Screening for Type 2 Diabetes and Dysglycemia. Epidemiologic Reviews 33:1, 63-87
CrossRef88
Mark WI Webster. (2011) Clinical practice and implications of recent diabetes trials. Current Opinion in Cardiology 26:4, 288-293
CrossRef89
John B. Garner, Paul A. Grayburn, Clyde W. Yancy. (2011) Best Clinical Trials Reported in 2010. The American Journal of Cardiology 108:1, 162-168
CrossRef90
Tomohiko Kanaoka, Kouichi Tamura, Tatsumi Moriya, Keiji Tanaka, Yusuke Konno, Satoshi Kondoh, Masao Toyoda, Tomoya Umezono, Tetsuya Fujikawa, Masato Ohsawa, Toru Dejima, Akinobu Maeda, Hiromichi Wakui, Sona Haku, Mai Yanagi, Hiroshi Mitsuhashi, Motoko Ozawa, Yasuko Okano, Nariaki Ogawa, Tadashi Yamakawa, Shunsaku Mizushima, Daisuke Suzuki, Satoshi Umemura. (2011) Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy – A Pilot Study. Clinical and Experimental Hypertension 33:4, 255-263
CrossRef91
Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Christina Hemmingsen, Jørn Wetterslev, Bianca Hemmingsen. 2011. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. .
CrossRef92
Gissette Reyes-Soffer, Carlos Rondon-Clavo, Henry N Ginsberg. (2011) Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:9, 1429-1438
CrossRef93
A. P. Agouridis, V. Tsimihodimos, T. D. Filippatos, A. D. Tselepis, M. S. Elisaf. (2011) High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia. Lipids 46:6, 521-528
CrossRef94
Jennifer G. Robinson, Anne C. Goldberg. (2011) Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 5:3, S18-S29
CrossRef95
Bernhard Föger. (2011) Lipid lowering therapy in type 2 diabetes. Wiener Medizinische Wochenschrift 161:11-12, 289-296
CrossRef96
M. J. Chapman, H. N. Ginsberg, P. Amarenco, F. Andreotti, J. Boren, A. L. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, B. G. Nordestgaard, K. K. Ray, Z. Reiner, M.-R. Taskinen, L. Tokgozoglu, A. Tybjaerg-Hansen, G. F. Watts, . (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 32:11, 1345-1361
CrossRef97
Bruno Vergès. (2011) Combination lipid therapy in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:9, 1393-1403
CrossRef98
George Dailey. (2011) Overall Mortality in Diabetes Mellitus: Where Do We Stand Today?. Diabetes Technology & Therapeutics 13:S1, S-65-S-74
CrossRef99
Jean-Pierre Déry. (2011) Controlling lipids after acute coronary syndromes: what is the best strategy?. Clinical Lipidology 6:3, 253-255
CrossRef100
Lisa M Younk, Lisa Uhl, Stephen N Davis. (2011) Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opinion on Drug Metabolism & Toxicology 7:6, 753-763
CrossRef101
Peter Libby, Paul M Ridker, Göran K. Hansson. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:7347, 317-325
CrossRef102
Michel Farnier. (2011) Safety review of combination drugs for hyperlipidemia. Expert Opinion on Drug Safety 10:3, 363-371
CrossRef103
Peter M Rothwell, Ale Algra, Pierre Amarenco. (2011) Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. The Lancet 377:9778, 1681-1692
CrossRef104
Carl J. Lavie, Richard V. Milani, James H. OʼKeefe. (2011) Dyslipidemia Intervention in Metabolic Syndrome: Emphasis on Improving Lipids and Clinical Event Reduction. The American Journal of the Medical Sciences 341:5, 388-393
CrossRef105
D. John Betteridge. (2011) Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 8:5, 278-290
CrossRef106
Syed M. Mohiuddin, Kamlesh M. Thakker, Carolyn M. Setze, Maureen T. Kelly. (2011) Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research and Opinion 27:5, 1067-1078
CrossRef107
Annett Stahn, Markolf Hanefeld. (2011) Multimodale Therapie von Fettstoffwechselstörungen. Clinical Research in Cardiology Supplements 6:S1, 10-16
CrossRef108
Harold E. Bays, Arvind Shah, Geraldine Macdonell, William V. Taggart, Barry Gumbiner. (2011) Effects of Coadministered Ezetimibe Plus Fenofibrate in Mixed Dyslipidemic Patients with Metabolic Syndrome. Metabolic Syndrome and Related Disorders 9:2, 135-142
CrossRef109
Carlos G Santos-Gallego, Francisco Torres, Juan José Badimón. (2011) The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. Clinical Lipidology 6:2, 181-208
CrossRef110
M. J. Cziraky, H. Tan, M. F. Bullano, J. Yu, R. Schiebinger, V. J. Willey. (2011) Impact of optimal lipid value achievement between 2005 and 2009 in patients with mixed dyslipidaemia on cardiovascular event rates. International Journal of Clinical Practice 65:4, 425-435
CrossRef111
David Siegel, Arthur L.M. Swislocki. (2011) The ACCORD Study: The Devil Is in the Details. Metabolic Syndrome and Related Disorders 9:2, 81-84
CrossRef112
Robert Krysiak, Anna Gdula-Dymek, Bogusław Okopien. (2011) Effect of Simvastatin and Fenofibrate on Cytokine Release and Systemic Inflammation in Type 2 Diabetes Mellitus With Mixed Dyslipidemia. The American Journal of Cardiology 107:7, 1010-1018.e1
CrossRef113
A. S. Wierzbicki. (2011) Niacin: the only vitamin that reduces cardiovascular events. International Journal of Clinical Practice 65:4, 379-385
CrossRef114
Alan J. Garber. (2011) Hypertension and Lipid Management in Prediabetic States. The Journal of Clinical Hypertension 13:4, 270-274
CrossRef115
D. S. H. Bell, F. Al Badarin, J. H. O’Keefe. (2011) Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 13:4, 313-325
CrossRef116
The ACCORD Study Group. (2011) Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine 364:9, 818-828
Full Text117
V. Pavlicek. (2011) Effekt von Fenofibrat auf die Nierenfunktion bei Patienten mit Diabetes mellitus Typ 2. Der Diabetologe 7:2, 115-116
CrossRef118
Lawrence A. Leiter, David H. Fitchett, Richard E. Gilbert, Milan Gupta, G.B. John Mancini, Philip A. McFarlane, Robert Ross, Hwee Teoh, Subodh Verma, Sonia Anand, Kathryn Camelon, Chi-Ming Chow, Jafna L. Cox, Jean-Pierre Després, Jacques Genest, Stewart B. Harris, David C.W. Lau, Richard Lewanczuk, Peter P. Liu, Eva M. Lonn, Ruth McPherson, Paul Poirier, Shafiq Qaadri, Rémi Rabasa-Lhoret, Simon W. Rabkin, Arya M. Sharma, Andrew W. Steele, James A. Stone, Jean-Claude Tardif, Sheldon Tobe, Ehud Ur. (2011) Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary). Canadian Journal of Cardiology 27:2, 124-131
CrossRef119
Lawrence A. Leiter, David H. Fitchett, Richard E. Gilbert, Milan Gupta, G.B. John Mancini, Philip A. McFarlane, Robert Ross, Hwee Teoh, Subodh Verma, Sonia Anand, Kathryn Camelon, Chi-Ming Chow, Jafna L. Cox, Jean-Pierre Després, Jacques Genest, Stewart B. Harris, David C.W. Lau, Richard Lewanczuk, Peter P. Liu, Eva M. Lonn, Ruth McPherson, Paul Poirier, Shafiq Qaadri, Rémi Rabasa-Lhoret, Simon W. Rabkin, Arya M. Sharma, Andrew W. Steele, James A. Stone, Jean-Claude Tardif, Sheldon Tobe, Ehud Ur. (2011) Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group. Canadian Journal of Cardiology 27:2, e1-e33
CrossRef120
Christoph H Saely, Veronika Drexel, Alexander Vonbank, Heinz Drexel. (2011) Lipid management in Type 2 diabetes: the case for combination therapy?. Therapy 8:2, 129-141
CrossRef121
Hana Rosolova, Barbora Nussbaumerova. (2011) Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. The EPMA Journal 2:1, 15-26
CrossRef122
G. Klose. (2011) Möglichkeiten und Grenzen der modernen Lipidtherapie. Der Internist 52:3, 328-335
CrossRef123
(2011) The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial. American Heart Journal 161:3, 538-543
CrossRef124
Ariel Brautbar, Christie M. Ballantyne. (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology
CrossRef125
2011. Lipids. , 262-288.
CrossRef126
Srinivasa P Munigoti, Alan Rees. (2011) Evidence for use of fibrates in diabetic dyslipidemia: are we looking hard enough?. Current Opinion in Lipidology 22:1, 76-77
CrossRef127
Mark Stolar. (2011) Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care. The American Journal of the Medical Sciences 341:2, 132-140
CrossRef128
Carlos A. Dujovne, Craig D. Williams, Matthew K. Ito. (2011) What Combination Therapy with a Statin, If Any, Would You Recommend?. Current Atherosclerosis Reports 13:1, 12-22
CrossRef129
Marshall Elam, Laura Lovato, Henry Ginsberg. (2011) The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clinical Lipidology 6:1, 9-20
CrossRef130
John B. Buse. (2011) Type 2 diabetes mellitus in 2010: Individualizing treatment targets in diabetes care. Nature Reviews Endocrinology 7:2, 67-68
CrossRef131
, T. M. E. Davis, R. Ting, J. D. Best, M. W. Donoghoe, P. L. Drury, D. R. Sullivan, A. J. Jenkins, R. L. O’Connell, M. J. Whiting, P. P. Glasziou, R. J. Simes, Y. A. Kesäniemi, V. J. Gebski, R. S. Scott, A. C. Keech. (2011) Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 54:2, 280-290
CrossRef132
Marshall Elam, Laura C Lovato, Henry Ginsberg. (2011) Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Current Opinion in Lipidology 22:1, 55-61
CrossRef133
Steven E. Nissen. (2011) Atherosclerosis in 2010: New therapeutic insights. Nature Reviews Cardiology 8:2, 70-72
CrossRef134
Nkechinyere Ijioma, Jennifer G Robinson. (2011) Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Review of Cardiovascular Therapy 9:2, 131-145
CrossRef135
P. Valensi, S. Picard. (2011) Lipids, lipid-lowering therapy and diabetes complications. Diabetes & Metabolism 37:1, 15-24
CrossRef136
Eric Bruckert, Julien Labreuche, Dominique Deplanque, Pierre-Jean Touboul, Pierre Amarenco. (2011) Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology 57:2, 267-272
CrossRef137
Alberto Cordero, Lorenzo Fácila, Ángeles Alonso, Pilar Mazón. (2011) Novedades en hipertensión arterial y diabetes de 2010. Revista Española de Cardiología 64, 20-29
CrossRef138
Christoph Wanner, Vera Krane. (2011) Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research 34:4, 209-217
CrossRef139
Michel Farnier, Armin Steinmetz, Kjetil Retterstøl, Albert Császár. (2011) Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study. Clinical Therapeutics 33:1, 1-12
CrossRef140
Philip J. Barter. (2011) The Causes and Consequences of Low Levels of High Density Lipoproteins in Patients with Diabetes. Diabetes & Metabolism Journal 35:2, 101
CrossRef141
Rhonda M. Cooper-DeHoff, Eric F. Egelund, Carl J. Pepine. (2011) Blood pressure lowering in patients with diabetes—one level might not fit all. Nature Reviews Cardiology 8:1, 42-49
CrossRef142
T. A. Jacobson. (2011) ‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. International Journal of Clinical Practice 65:1, 82-101
CrossRef143
Vivencio Barrios Alonso, Carlos Escobar Cervantes. (2011) Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. Revista Española de Cardiología Suplementos 11, 29-35
CrossRef144
Sungjin Chung, Cheol Whee Park. (2011) Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy. Diabetes & Metabolism Journal 35:4, 327
CrossRef145
Yasuo Oshima. (2011) Characteristics of Drug-Associated Rhabdomyolysis: Analysis of 8,610 Cases Reported to the U.S. Food and Drug Administration. Internal Medicine 50:8, 845-853
CrossRef146
Ebenezer A. Nyenwe, Terri W. Jerkins, Guillermo E. Umpierrez, Abbas E. Kitabchi. (2011) Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 60:1, 1-23
CrossRef147
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef148
Robert S. Rosenson, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Boaz Hirshberg, James C. Stolzenbach, Laura A. Williams. (2010) Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy
CrossRef149
Martijn CGJ Brouwers, Jacqueline de Graaf, Marleen MJ van Greevenbroek, Nicolaas Schaper, Coen DA Stehouwer, Anton FH Stalenhoef. (2010) Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus. Current Opinion in Lipidology 21:6, 530-538
CrossRef150
Allan Sniderman, Ken Williams, Jacqueline de Graaf. (2010) Non-HDL C equals apolipoprotein B: except when it does not!. Current Opinion in Lipidology 21:6, 518-524
CrossRef151
Michel P Hermans, Jean-Charles Fruchart. (2010) Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. Clinical Lipidology 5:6, 811-826
CrossRef152
Tara I. Chang, Alfred K. Cheung, Glenn M. Chertow. (2010) Blood Pressure Control in Type 2 Diabetes Mellitus. American Journal of Kidney Diseases 56:6, 1029-1031
CrossRef153
Rajesh Peter, Elizabeth Reilly, Sony Anthony. (2010) Therapy and clinical trials: fibrate therapy in type 2 diabetes – where are we now?. Current Opinion in Lipidology 21:6, 554-555
CrossRef154
(2010) Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine 363:22, 2171-2174
Full Text155
Robert Krysiak, Bogusław Okopien. (2010) The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: A preliminary report. Atherosclerosis 213:1, 325-328
CrossRef156
A. Ceriello. (2010) The glucose triad and its role in comprehensive glycaemic control: current status, future management. International Journal of Clinical Practice 64:12, 1705-1711
CrossRef157
Sophia Zoungas, Anushka Patel. (2010) Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Annals of the New York Academy of Sciences 1212:1, 29-40
CrossRef158
Emilie Mas, Trevor A. Mori. (2010) Coenzyme Q10 and Statin Myalgia: What is the Evidence?. Current Atherosclerosis Reports 12:6, 407-413
CrossRef159
GF Watts, F Karpe. (2010) More than meets the eye: the ACCORD trial and use of statin-fibrate combination in type 2 diabetes mellitus. Practical Diabetes International 27:8, 326-328
CrossRef160
Ganesh P Devendra, Richard A Krasuski. (2010) Therapy and clinical trials. Current Opinion in Lipidology 21:5, 471-472
CrossRef161
Nicola Abate, Manisha Chandalia. (2010) The ACCORD LIPID Trial. Metabolic Syndrome and Related Disorders 8:5, 373-374
CrossRef162
Terry A Jacobson, Peter H Jones, Eli M Roth. (2010) Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. Clinical Lipidology 5:5, 627-649
CrossRef163
Carl J. Pepine, Terry A. Jacobson, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Alex Gold, James C. Stolzenbach, Laura A. Williams. (2010) Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies. Clinical Cardiology 33:10, 609-619
CrossRef164
George Bakris, Joseph Vassalotti, Eberhard Ritz, Christoph Wanner, George Stergiou, Mark Molitch, Richard Nesto, George A Kaysen, James R Sowers. (2010) National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International 78:8, 726-736
CrossRef165
F Ismail-Beigi, T Craven, S Genuth, I Hramiack, D Karl. (2010) Mixed messages on systemic therapies for diabetic retinopathy – Authors' reply. The Lancet 376:9751, 1462
CrossRef166
Pierre Delanaye, André J Scheen. (2010) Effects of fibrates on cardiovascular outcomes. The Lancet 376:9746, 1051
CrossRef167
Michel Farnier, Jean Ducobu, Leszek Bryniarski. (2010) Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy. The American Journal of Cardiology 106:6, 787-792
CrossRef168
Milan Gupta, Paul E Szmitko, Michelle Tsigoulis, Manoela F B Braga, Mahesh Kajil, Sheriar Herjikaka, Adrian Quan, Hwee Teoh, Subodh Verma. (2010) Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease. Journal of Cardiovascular Pharmacology 56:3, 241-245
CrossRef169
Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, 649-661
CrossRef170
Rajesh Tota-Maharaj, Andrew P Defilippis, Roger S Blumenthal, Michael J Blaha. (2010) A practical approach to the metabolic syndrome: review of current concepts and management. Current Opinion in Cardiology 22:5, 502-512
CrossRef171
Marie Russell, Angela Silverman, Jerome L. Fleg, Elisa T. Lee, Mihriye Mete, Matthew Weir, Charlton Wilson, Fawn Yeh, Barbara V. Howard, Wm. James Howard. (2010) Achieving lipid targets in adults with type 2 diabetes: The Stop Atherosclerosis in Native Diabetics Study. Journal of Clinical Lipidology 4:5, 435-443
CrossRef172
Mariela Glandt, Itamar Raz. (2010) Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go?. Nature Reviews Endocrinology 6:9, 483-484
CrossRef173
Domingo Orozco Beltrán, Carlos de la Sen Fernández, Vicente Gil Guillén, Concepción Carratalá Munuera, Jorge Navarro Pérez. (2010) La diabetes mellitus y el riesgo cardiovascular. ¿Es necesario el tratamiento integral de la diabetes mellitus tipo 2 y los factores de riesgo cardiovascular?. Atención Primaria 42, 16-23
CrossRef174
Sergio Fazio, MacRae F. Linton. (2010) High-density lipoprotein therapeutics and cardiovascular prevention. Journal of Clinical Lipidology 4:5, 411-419
CrossRef175
Vlado Perkovic, Min Jun, Bruce Neal. (2010) Effects of fibrates on cardiovascular outcomes – Authors' reply. The Lancet 376:9746, 1051-1052
CrossRef176
, M.-R. Taskinen, P. J. Barter, C. Ehnholm, D. R. Sullivan, K. Mann, J. Simes, J. D. Best, S. Hamwood, A. C. Keech. (2010) Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 53:9, 1846-1855
CrossRef177
Smita Negi, Christie M. Ballantyne. (2010) Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. Journal of Clinical Lipidology 4:5, 365-370
CrossRef178
Justin MS Lee, Robin P Choudhury. (2010) Atherosclerosis regression and high-density lipoproteins. Expert Review of Cardiovascular Therapy 8:9, 1325-1334
CrossRef179
Stephen A. Brietzke. (2010) A Personalized Approach to Metabolic Aspects of Obesity. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:5, 499-510
CrossRef180
Peter P. Toth. (2010) Fibrate Therapy in the Management of Diabetic Dyslipidemia: There is No ACCORD to be Found. Current Atherosclerosis Reports 12:5, 331-335
CrossRef181
(2010) Combination Lipid Therapy in Type 2 Diabetes. New England Journal of Medicine 363:7, 692-695
Full Text182
Mark J Cziraky, Tyan Thomas. (2010) Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia. Clinical Lipidology 5:4, 527-541
CrossRef183
Matthew A. Cavender, A. Michael Lincoff. (2010) Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist. American Journal Cardiovascular Drugs 10:4, 209-216
CrossRef184
Anthony S Wierzbicki. (2010) Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Current Opinion in Lipidology 21:4, 352-358
CrossRef185
Ishwarlal Jialal, William Amess, Manpreet Kaur. (2010) Management of Hypertriglyceridemia in the Diabetic Patient. Current Diabetes Reports 10:4, 316-320
CrossRef186
The ACCORD Study Group and ACCORD Eye Study Group. (2010) Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine 363:3, 233-244
Full Text187
Jesús Millán Núñez-Cortés, Juan Pedro Botet Montoya, Xavier Pintó Sala. (2010) Dislipemia aterogénica: una llamada de atención sobre su papel en el riesgo residual. Clínica e Investigación en Arteriosclerosis 22:4, 162-166
CrossRef188
Eli M. Roth, James M. McKenney, Maureen T. Kelly, Carolyn M. Setze, Dawn M. Carlson, Alex Gold, James C. Stolzenbach, Laura A. Williams, Peter H. Jones. (2010) Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia. American Journal Cardiovascular Drugs 10:3, 175-186
CrossRef189
Abhaya Gupta, Veronique Guyomard, M. Justin S. Zaman, Habib U. Rehman, Phyo Kyaw Myint. (2010) Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in Therapy 27:6, 348-364
CrossRef190
M Fisher. (2010) Half full, half empty, or negative? Results of recent clinical trials. Practical Diabetes International 27:5, 174-175
CrossRef191
Vicente Correa Jr, Miguel Gus, Flávio Danni Fuchs. (2010) Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?. Expert Review of Cardiovascular Therapy 8:6, 775-779
CrossRef192
Min Jun, Celine Foote, Jicheng Lv, Bruce Neal, Anushka Patel, Stephen J Nicholls, Diederick E Grobbee, Alan Cass, John Chalmers, Vlado Perkovic. (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet 375:9729, 1875-1884
CrossRef193
Bart Staels. (2010) Fibrates in CVD: a step towards personalised medicine. The Lancet 375:9729, 1847-1848
CrossRef194
Guillaume Pare, Sonia S Anand. (2010) Mendelian randomisation, triglycerides, and CHD. The Lancet 375:9726, 1584-1586
CrossRef195
The ACCORD Study Group. (2010) Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine 362:17, 1575-1585
Full Text196
Nilsson, Peter M., . (2010) ACCORD and Risk-Factor Control in Type 2 Diabetes. New England Journal of Medicine 362:17, 1628-1630
Full Text197
Caroline S. Fox. (2010) Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. Trends in Cardiovascular Medicine 20:3, 90-95
CrossRef198
Lena Burri, G. Hege Thoresen, Rolf K. Berge. (2010) The Role of PPARα Activation in Liver and Muscle. PPAR Research 2010, 1-11
CrossRef
- Letters
